2017 Chinese expert consensus on the clinical application of serum marker for thyroid cancer

In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There are great differences between the clinical diagnostic and therapeutic modes and disease management of thyroid cancer employed by various medical institutions in China, particularly with regard to the clinical application of serum marker of thyroid cancer. To this end, the China Anti-Cancer Association Thyroid Cancer Specialized Committee Chinese Association of Thyroid Oncology organized this compilation of Expert Consensus on Clinical Application of Serum Marker of Thyroid Cancer to help and impel relevant clinical institutions and professionals to standardize clinical diagnosis, treatment, and long-term management of thyroid cancer, and to properly utilize the serum marker for scientific auxiliary clinical diagnosis and assessment of thyroid cancer before and after operation. A total of 14 recommendations have been put forward in this consensus for measuring the levels of serum marker of thyroid cancer. In view of the limited references, especially regarding the perspective data currently available at home and abroad, omissions are inevitable. Moreover, we also hope that the professionals can give more valuable suggestions for regular revision in the future (see categories of recommendations in Table 1 and detailed recommendations in Table 2)